董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mary Thistle | 女 | Director | 66 | 4.50万美元 | 2.34 | 2026-03-10 |
| Matthew Roden | 男 | President, Chief Executive Officer and Director | 55 | 91.47万美元 | 140.35 | 2026-03-10 |
| Todd Foley | 男 | Director and Chair | 54 | 未披露 | 423.96 | 2026-03-10 |
| Ken Herrmann | 男 | Director | 48 | 7.00万美元 | 8.43 | 2026-03-10 |
| Michael A. Sherman | 男 | Director | 59 | 1.88万美元 | 未持股 | 2026-03-10 |
| Helen S. Kim | 女 | Director | 63 | 未披露 | 583.34 | 2026-03-10 |
| Lloyd M. Segal | 男 | Director | 62 | 4.50万美元 | 8.81 | 2026-03-10 |
| Oleg Nodelman | 男 | Director | 49 | 未披露 | 588.01 | 2026-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kyle D. Kuvalanka | 男 | Chief Financial Officer | 57 | 未披露 | 未持股 | 2026-03-10 |
| Matthew Roden | 男 | President, Chief Executive Officer and Director | 55 | 91.47万美元 | 140.35 | 2026-03-10 |
| Paul L. Feldman | 男 | Chief Scientific Officer | 65 | 64.24万美元 | 42.94 | 2026-03-10 |
| Shulamit Ron Bigger | 女 | Chief Operating Officer | 45 | 140.91万美元 | 未持股 | 2026-03-10 |
| Akos Czibere | 男 | Chief Medical Officer | 48 | 90.27万美元 | 16.33 | 2026-03-10 |
| Tyler Benedum | 男 | Chief Technical Officer | 50 | 未披露 | 未持股 | 2026-03-10 |
董事简历
中英对照 | 中文 | 英文- Mary Thistle
-
Mary Thistle自2018年3月以来一直担任我们的董事会成员。Thistle女士自2018年1月起担任非营利生物技术组织比尔及梅林达·盖茨医学研究所的办公室主任。在此之前，她曾在基因治疗公司DimensionTherapeutics，Inc.担任高级领导职务，包括2016年至2017年担任首席运营官，2015年至2016年担任首席商务官。在加入DimensionTherapeutics，Inc.之前，她在生物制药公司CubistPharmaceuticals，Inc.工作了6年，担任过多个领导职位，包括2014年至2015年担任高级副总裁，业务开发Vice President，2012年至2013年担任业务开发高级总监，2009年至2012年担任业务开发高级总监。在此之前，她在Viacell，Inc.和PerkinElmer Inc.担任多个职位。Thistle女士担任Enterome SA的董事，这是一家位于法国巴黎的制药和诊断公司，也是Cocoon Biotech Inc.的董事。Thistle女士拥有波士顿马萨诸塞大学（University of Massachusetts，Boston）会计学士学位。
Mary Thistle has served as a member of Aktis Oncology, Inc.'s board of directors since January 2025. Ms. Thistle previously served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, or the Medical Research Institute, a non profit biotech organization, from the fall of 2020 to June 2022, and previously served as the organization's Chief of Staff from January 2018 to the fall of 2020. Prior to the Medical Research Institute, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including as Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Ms. Thistle held various leadership positions at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, including as Senior Vice President, Business Development from 2014 to 2015, Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to Cubist Pharmaceuticals, she held various positions at ViaCell, Inc. and PerkinElmer LAS Inc. Ms. Thistle has served on the board of directors of Cullinan Therapeutics, Inc. (Nasdaq: CGEM), since August 2024, Q32 Bio Inc. (Nasdaq: QTTB) (formerly known as Homology Medicines, Inc.), since March 2024, Entrada Therapeutics, Inc., since May 2021 and Vigil Neuroscience, Inc., since April 2022, as well as on the boards of multiple private companies. Ms. Thistle also previously served on the board of directors of Alaunos Therapeutics, Inc. (formerly known as Ziopharm Oncology, Inc.) from November 2020 to December 2023. Ms. Thistle holds a BS in Business and Accounting from the University of Massachusetts, Boston and is a former Certified Public Accountant. - Mary Thistle自2018年3月以来一直担任我们的董事会成员。Thistle女士自2018年1月起担任非营利生物技术组织比尔及梅林达·盖茨医学研究所的办公室主任。在此之前，她曾在基因治疗公司DimensionTherapeutics，Inc.担任高级领导职务，包括2016年至2017年担任首席运营官，2015年至2016年担任首席商务官。在加入DimensionTherapeutics，Inc.之前，她在生物制药公司CubistPharmaceuticals，Inc.工作了6年，担任过多个领导职位，包括2014年至2015年担任高级副总裁，业务开发Vice President，2012年至2013年担任业务开发高级总监，2009年至2012年担任业务开发高级总监。在此之前，她在Viacell，Inc.和PerkinElmer Inc.担任多个职位。Thistle女士担任Enterome SA的董事，这是一家位于法国巴黎的制药和诊断公司，也是Cocoon Biotech Inc.的董事。Thistle女士拥有波士顿马萨诸塞大学（University of Massachusetts，Boston）会计学士学位。
- Mary Thistle has served as a member of Aktis Oncology, Inc.'s board of directors since January 2025. Ms. Thistle previously served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, or the Medical Research Institute, a non profit biotech organization, from the fall of 2020 to June 2022, and previously served as the organization's Chief of Staff from January 2018 to the fall of 2020. Prior to the Medical Research Institute, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including as Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Ms. Thistle held various leadership positions at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, including as Senior Vice President, Business Development from 2014 to 2015, Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to Cubist Pharmaceuticals, she held various positions at ViaCell, Inc. and PerkinElmer LAS Inc. Ms. Thistle has served on the board of directors of Cullinan Therapeutics, Inc. (Nasdaq: CGEM), since August 2024, Q32 Bio Inc. (Nasdaq: QTTB) (formerly known as Homology Medicines, Inc.), since March 2024, Entrada Therapeutics, Inc., since May 2021 and Vigil Neuroscience, Inc., since April 2022, as well as on the boards of multiple private companies. Ms. Thistle also previously served on the board of directors of Alaunos Therapeutics, Inc. (formerly known as Ziopharm Oncology, Inc.) from November 2020 to December 2023. Ms. Thistle holds a BS in Business and Accounting from the University of Massachusetts, Boston and is a former Certified Public Accountant.
- Matthew Roden
-
Matthew Roden担任我们的董事会主席。Roden博士在整个医疗保健生态系统积累了广泛的经验，曾担任大型生物制药公司的高级领导者，领导了股权资本市场的生物技术研究，并磨练了他作为免疫学家和结构生物学家的科学基础。Roden博士目前担任Aktis Oncology的总裁兼首席执行官，以及MPM Capital的执行合伙人。他也是iTeos Therapeutics NASDAQ:ITOS、Aktis Oncology和NextPoint Therapeutics的董事会成员。从2019年到2020年，Roden博士担任百时美施贵宝BMS的高级副总裁兼企业战略主管。在此职位上，Roden博士为合并的BMS-Celgene实体和初始投资组合优化提供了首个战略计划。从2016年到2019年，他担任战略公司发展和全球BD评估主管，负责并购，结构化交易，战略股权投资和资产剥离，以及所有治疗类别的领先业务发展搜索和评估（S&E）活动。Roden博士还曾在代表外部创新的研发领导团队中任职。Roden博士领导或监督了100多项业务开发交易，这些交易的累计价值超过1250亿美元，包括BMS’；收购Celgene，这是迄今为止医疗保健领域最大的收购。他曾担任瑞银投资银行的生物技术股票研究主管；摩根大通和美国银行美林的高级生物技术股票分析师；以及瑞士信贷第一波士顿的合伙人。除了对整个生物技术领域的研究报道外，罗登博士和他的团队还在2005年至2016年期间提供了24次股票发行的股票研究尽职调查和投资者参与，初始价值总计33亿美元。他在爱因斯坦医学院获得博士学位，主要研究免疫相关分子的结构生物学。在完成这项研究生工作之前，他在马里兰州贝塞斯达的国家癌症研究所获得了免疫肿瘤学的博士后临床研究奖学金。Roden博士拥有乔治敦大学的硕士学位和乔治梅森大学的学士学位。
Matthew Roden has served as Aktis Oncology, Inc.'s President and Chief Executive Officer and as a member of Aktis Oncology, Inc.'s board of directors since September 2020. Since August 2020, Dr. Roden has worked as an Entrepreneur Partner at MPM BioImpact LLC, a biotechnology investment firm. Dr. Roden also serves as a member of the board of directors of Orna Therapeutics, Inc., a biotechnology company, since May 2024 following its acquisition of ReNAgade Therapeutics Inc. where he had served on the board of directors since January 2023. Previously, Dr. Roden served on the board of directors of NextPoint Therapeutics, Inc., a clinical stage biotechnology company, from October 2020 to December 2024, iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical stage biopharmaceutical company, from November 2020 to February 2023, and as Chairman of Tumeric Acquisition Corporation, a special purpose acquisition company, from September 2020 to December 2022. From November 2019 to August 2020, he was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb, a global pharmaceutical company. From May 2016 to November 2019, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global Business Development Assessment at Bristol Myers Squibb, leading business development search and evaluation activities for all therapeutic categories. Dr. Roden also previously worked as an equity research analyst at UBS Investment Bank and J.P. Morgan. Dr. Roden holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, an MS from Georgetown University, a BS from George Mason University and was a pre doctoral fellow at the National Cancer Institute. - Matthew Roden担任我们的董事会主席。Roden博士在整个医疗保健生态系统积累了广泛的经验，曾担任大型生物制药公司的高级领导者，领导了股权资本市场的生物技术研究，并磨练了他作为免疫学家和结构生物学家的科学基础。Roden博士目前担任Aktis Oncology的总裁兼首席执行官，以及MPM Capital的执行合伙人。他也是iTeos Therapeutics NASDAQ:ITOS、Aktis Oncology和NextPoint Therapeutics的董事会成员。从2019年到2020年，Roden博士担任百时美施贵宝BMS的高级副总裁兼企业战略主管。在此职位上，Roden博士为合并的BMS-Celgene实体和初始投资组合优化提供了首个战略计划。从2016年到2019年，他担任战略公司发展和全球BD评估主管，负责并购，结构化交易，战略股权投资和资产剥离，以及所有治疗类别的领先业务发展搜索和评估（S&E）活动。Roden博士还曾在代表外部创新的研发领导团队中任职。Roden博士领导或监督了100多项业务开发交易，这些交易的累计价值超过1250亿美元，包括BMS’；收购Celgene，这是迄今为止医疗保健领域最大的收购。他曾担任瑞银投资银行的生物技术股票研究主管；摩根大通和美国银行美林的高级生物技术股票分析师；以及瑞士信贷第一波士顿的合伙人。除了对整个生物技术领域的研究报道外，罗登博士和他的团队还在2005年至2016年期间提供了24次股票发行的股票研究尽职调查和投资者参与，初始价值总计33亿美元。他在爱因斯坦医学院获得博士学位，主要研究免疫相关分子的结构生物学。在完成这项研究生工作之前，他在马里兰州贝塞斯达的国家癌症研究所获得了免疫肿瘤学的博士后临床研究奖学金。Roden博士拥有乔治敦大学的硕士学位和乔治梅森大学的学士学位。
- Matthew Roden has served as Aktis Oncology, Inc.'s President and Chief Executive Officer and as a member of Aktis Oncology, Inc.'s board of directors since September 2020. Since August 2020, Dr. Roden has worked as an Entrepreneur Partner at MPM BioImpact LLC, a biotechnology investment firm. Dr. Roden also serves as a member of the board of directors of Orna Therapeutics, Inc., a biotechnology company, since May 2024 following its acquisition of ReNAgade Therapeutics Inc. where he had served on the board of directors since January 2023. Previously, Dr. Roden served on the board of directors of NextPoint Therapeutics, Inc., a clinical stage biotechnology company, from October 2020 to December 2024, iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical stage biopharmaceutical company, from November 2020 to February 2023, and as Chairman of Tumeric Acquisition Corporation, a special purpose acquisition company, from September 2020 to December 2022. From November 2019 to August 2020, he was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb, a global pharmaceutical company. From May 2016 to November 2019, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global Business Development Assessment at Bristol Myers Squibb, leading business development search and evaluation activities for all therapeutic categories. Dr. Roden also previously worked as an equity research analyst at UBS Investment Bank and J.P. Morgan. Dr. Roden holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, an MS from Georgetown University, a BS from George Mason University and was a pre doctoral fellow at the National Cancer Institute.
- Todd Foley
-
Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Todd Foley is Aktis Oncology, Inc.'s co founder and has served as Chair of Aktis Oncology, Inc.'s board of directors since August 2020. Since 1999, Mr. Foley has worked at MPM BioImpact LLC, a biotechnology investment firm where he has served as a Managing Director focusing on venture investments in biotech companies. Mr. Foley has previously served on the board of directors of Entrada Therapeutics, Inc. (Nasdaq: TRDA), from December 2018 to June 2023, Repare Therapeutics Inc. (Nasdaq: RPTX), from June 2017 to June 2024, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), from 2014 to June 2021, and Chiasma Inc., from May 2008 until its merger with Amryt Pharma plc in August 2021. Mr. Foley also serves on the board of directors of several other privately held life sciences and biotechnology companies. Mr. Foley received a BS in Chemistry from the Massachusetts Institute of Technology and an MBA from Harvard Business School. - Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Todd Foley is Aktis Oncology, Inc.'s co founder and has served as Chair of Aktis Oncology, Inc.'s board of directors since August 2020. Since 1999, Mr. Foley has worked at MPM BioImpact LLC, a biotechnology investment firm where he has served as a Managing Director focusing on venture investments in biotech companies. Mr. Foley has previously served on the board of directors of Entrada Therapeutics, Inc. (Nasdaq: TRDA), from December 2018 to June 2023, Repare Therapeutics Inc. (Nasdaq: RPTX), from June 2017 to June 2024, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), from 2014 to June 2021, and Chiasma Inc., from May 2008 until its merger with Amryt Pharma plc in August 2021. Mr. Foley also serves on the board of directors of several other privately held life sciences and biotechnology companies. Mr. Foley received a BS in Chemistry from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
- Ken Herrmann
-
Ken Herrmann一直担任德国埃森大学核医学系主任和系主任。在此之前，Herrmann博士是加州大学洛杉矶分校分子和医学药理学系的终身副教授，从2015年到2021年6月。Herrmann博士还担任EANM肿瘤与治疗学委员会主席，以及两家私营生物技术公司的董事会成员。目前担任核医学JNal的版面编辑和欧洲Eurology的影像编辑。Herrmann博士在柏林洪堡大学获得医学博士学位和医学博士学位，并在苏黎世大学获得MBA学位。
Ken Herrmann has served as a member of Aktis Oncology, Inc.'s board of directors since May 2024. Since 2016, Dr. Herrmann has been the Director and Chair of the Department of Nuclear Medicine at the Universittsmedizin Essen in Germany. Prior to that, Dr. Herrmann was a tenured Associate Professor at the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles, from 2015 until June 2021. Dr. Herrmann also served as the Chair of the EANM Oncology & Theranostics Committee and on the board of directors of two privately held biotechnology companies. Currently he serves as a Section Editor of the Journal of Nuclear Medicine and as Imaging Editor of European Eurology. Dr. Herrmann received an MD and a Doctorate degree in Medicine from the Humboldt Universitt Berlin and an MBA from the University of Zurich. - Ken Herrmann一直担任德国埃森大学核医学系主任和系主任。在此之前，Herrmann博士是加州大学洛杉矶分校分子和医学药理学系的终身副教授，从2015年到2021年6月。Herrmann博士还担任EANM肿瘤与治疗学委员会主席，以及两家私营生物技术公司的董事会成员。目前担任核医学JNal的版面编辑和欧洲Eurology的影像编辑。Herrmann博士在柏林洪堡大学获得医学博士学位和医学博士学位，并在苏黎世大学获得MBA学位。
- Ken Herrmann has served as a member of Aktis Oncology, Inc.'s board of directors since May 2024. Since 2016, Dr. Herrmann has been the Director and Chair of the Department of Nuclear Medicine at the Universittsmedizin Essen in Germany. Prior to that, Dr. Herrmann was a tenured Associate Professor at the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles, from 2015 until June 2021. Dr. Herrmann also served as the Chair of the EANM Oncology & Theranostics Committee and on the board of directors of two privately held biotechnology companies. Currently he serves as a Section Editor of the Journal of Nuclear Medicine and as Imaging Editor of European Eurology. Dr. Herrmann received an MD and a Doctorate degree in Medicine from the Humboldt Universitt Berlin and an MBA from the University of Zurich.
- Michael A. Sherman
-
Michael A. Sherman，2006年10月起，他成为首席财务官；1994年12月至2006年10月，他担任过多个行政职务，其中距今最近的是2004年5月至2006年10月在Guidant Corporation（心血管疾病设备制造商，2006年4月被Boston Scientific Corporation这一医药设备公司收购）担任的财务部及策略规划部副总裁。他获有迪堡大学经济学学士学位以及达特茅斯商学院工商管理硕士学位。
Michael A. Sherman has served as a member of Aktis Oncology, Inc.'s board of directors since August 2025. Mr. Sherman currently serves on the board of directors of Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a publicly traded biopharmaceutical company, a position he has held since May 2021. Mr. Sherman previously served from April 2019 to July 2023 as Chief Executive Officer and a member of the board of directors of Chimerix, Inc., a publicly traded biopharmaceutical company, and as chair of the board of directors of Chimerix from August 2023 to April 2025. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by Novartis. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation. He has also served on the board of directors of Biospecifics Technologies, Inc. from April 2020 until its acquisition by Endo Pharmaceuticals in December 2020, and he served as chair of the board of directors of the Children's Museum of Indianapolis from January 2012 until December 2022. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. - Michael A. Sherman，2006年10月起，他成为首席财务官；1994年12月至2006年10月，他担任过多个行政职务，其中距今最近的是2004年5月至2006年10月在Guidant Corporation（心血管疾病设备制造商，2006年4月被Boston Scientific Corporation这一医药设备公司收购）担任的财务部及策略规划部副总裁。他获有迪堡大学经济学学士学位以及达特茅斯商学院工商管理硕士学位。
- Michael A. Sherman has served as a member of Aktis Oncology, Inc.'s board of directors since August 2025. Mr. Sherman currently serves on the board of directors of Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a publicly traded biopharmaceutical company, a position he has held since May 2021. Mr. Sherman previously served from April 2019 to July 2023 as Chief Executive Officer and a member of the board of directors of Chimerix, Inc., a publicly traded biopharmaceutical company, and as chair of the board of directors of Chimerix from August 2023 to April 2025. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by Novartis. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation. He has also served on the board of directors of Biospecifics Technologies, Inc. from April 2020 until its acquisition by Endo Pharmaceuticals in December 2020, and he served as chair of the board of directors of the Children's Museum of Indianapolis from January 2012 until December 2022. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar.
- Helen S. Kim
-
Helen S. Kim，她目前担任NGM Biopharmaceuticals, Inc.的战略顾问。从2009年8月到2012年1月，她担任其首席商务官。在加入NGM之前的2008年12月到2009年6月，她曾是TRF Pharma的首席执行官。在TRF Pharma任职之前的2008年1月至2008年7月，她担任 Kosan Biosciences, Inc.的总裁和首席执行官。从2003年8月到2007年12月，她担任the Gordon and Betty Moore Foundation的项目总监。从2002年到2003年，她担任Affymax, Inc.的首席商务官。在Affymax任职之前的1999年到2002年，她曾是Onyx Pharmaceuticals, Inc.的高级副总裁负责公司发展。从1989年到1998年，她担任Chiron Corporation的总裁负责战略市场营销。她目前在Immunocellular Therapeutics, Ltd.（一个上市的生物科技公司）、 West Coast Clinical Trial Global（私人全球合同制研究组织）和ForSight VISION4 Inc.（私人眼科保健设备公司）的董事会任职。她获得美国西北大学（ Northwestern University）化学工程学士学位和芝加哥大学（University of Chicago）的工商管理硕士学位。
Helen S. Kim has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since April 2019, Ms. Kim has been a Senior Managing Director of Vida Ventures, LLC, a venture capital firm. From March 2018 to March 2019, Ms. Kim was a Partner at The Column Group, a venture capital firm. Previously, Ms. Kim was the Executive Vice President, Business Development at Kite Pharma, Inc. from June 2014 to January 2018, where she led the business and corporate development initiatives resulting in its acquisition by Gilead in 2017. From August 2009 to November 2014, Ms. Kim worked at NGM Biopharmaceuticals Inc., a biopharmaceutical company, serving in the role of Chief Business Officer from August 2009 to July 2012 and Strategic Advisor from July 2012 to November 2014. From 2007 to 2008, she served as the Chief Executive Officer and President of Kosan Biosciences Inc., a pharmaceutical company, prior to the sale of the company to Bristol Myers Squibb. Prior to this, Ms. Kim held various executive and leadership positions at Affymax, Inc., a biopharmaceutical company, Onyx Pharmaceuticals, Inc., a biopharmaceutical company and subsidiary of Amgen Inc., Protein Design Labs, Inc., a technology company, and Chiron Corporation, a biotechnology company and a subsidiary of Novartis AG. From August 2003 to November 2007, Ms. Kim also served as Chief Program Officer for the Gordon and Betty Moore Foundation, a nonprofit organization. Ms. Kim currently serves on the board of directors of Phylaxis Bioscience, LLC, since September 2024, Prothena Corporation plc (Nasdaq: PRTA), since August 2022, and on the board of directors of the privately held companies, InduPro Labs, since February 2022, Protego Biopharma, since October 2021, IconOVir Bio, Inc., since December 2020, ReCode Therapeutics, Inc., since March 2020, and A2 Biotherapeutics, Inc., since April 2019. Ms. Kim previously served on the board of directors of Applied Molecular Transport, Inc., from October 2018 until April 2022. Ms. Kim received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago. - Helen S. Kim，她目前担任NGM Biopharmaceuticals, Inc.的战略顾问。从2009年8月到2012年1月，她担任其首席商务官。在加入NGM之前的2008年12月到2009年6月，她曾是TRF Pharma的首席执行官。在TRF Pharma任职之前的2008年1月至2008年7月，她担任 Kosan Biosciences, Inc.的总裁和首席执行官。从2003年8月到2007年12月，她担任the Gordon and Betty Moore Foundation的项目总监。从2002年到2003年，她担任Affymax, Inc.的首席商务官。在Affymax任职之前的1999年到2002年，她曾是Onyx Pharmaceuticals, Inc.的高级副总裁负责公司发展。从1989年到1998年，她担任Chiron Corporation的总裁负责战略市场营销。她目前在Immunocellular Therapeutics, Ltd.（一个上市的生物科技公司）、 West Coast Clinical Trial Global（私人全球合同制研究组织）和ForSight VISION4 Inc.（私人眼科保健设备公司）的董事会任职。她获得美国西北大学（ Northwestern University）化学工程学士学位和芝加哥大学（University of Chicago）的工商管理硕士学位。
- Helen S. Kim has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since April 2019, Ms. Kim has been a Senior Managing Director of Vida Ventures, LLC, a venture capital firm. From March 2018 to March 2019, Ms. Kim was a Partner at The Column Group, a venture capital firm. Previously, Ms. Kim was the Executive Vice President, Business Development at Kite Pharma, Inc. from June 2014 to January 2018, where she led the business and corporate development initiatives resulting in its acquisition by Gilead in 2017. From August 2009 to November 2014, Ms. Kim worked at NGM Biopharmaceuticals Inc., a biopharmaceutical company, serving in the role of Chief Business Officer from August 2009 to July 2012 and Strategic Advisor from July 2012 to November 2014. From 2007 to 2008, she served as the Chief Executive Officer and President of Kosan Biosciences Inc., a pharmaceutical company, prior to the sale of the company to Bristol Myers Squibb. Prior to this, Ms. Kim held various executive and leadership positions at Affymax, Inc., a biopharmaceutical company, Onyx Pharmaceuticals, Inc., a biopharmaceutical company and subsidiary of Amgen Inc., Protein Design Labs, Inc., a technology company, and Chiron Corporation, a biotechnology company and a subsidiary of Novartis AG. From August 2003 to November 2007, Ms. Kim also served as Chief Program Officer for the Gordon and Betty Moore Foundation, a nonprofit organization. Ms. Kim currently serves on the board of directors of Phylaxis Bioscience, LLC, since September 2024, Prothena Corporation plc (Nasdaq: PRTA), since August 2022, and on the board of directors of the privately held companies, InduPro Labs, since February 2022, Protego Biopharma, since October 2021, IconOVir Bio, Inc., since December 2020, ReCode Therapeutics, Inc., since March 2020, and A2 Biotherapeutics, Inc., since April 2019. Ms. Kim previously served on the board of directors of Applied Molecular Transport, Inc., from October 2018 until April 2022. Ms. Kim received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.
- Lloyd M. Segal
-
Lloyd M. Segal ，他一直任职公司的董事会（2007年12月以来）。2010年2月以来，他一直担任Persistence Capital Partners公司（专注于医疗保健的私人股本基金）的普通合伙人。从1998年到2008年，他担任 Caprion Pharmaceuticals公司（于2007年成为Thallion Pharmaceuticals公司）的总裁兼首席执行官，在那里他仍然是董事会主席。他此前曾担任McKinsey公司的管理顾问，以及Advanced Bioconcept公司的总裁兼首席执行官。他目前任职Thallion Pharmaceuticals公司和 GBC American Growth Fund公司的董事会，以及 the School of Science at Brandeis University的顾问委员会。
Lloyd M. Segal has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Mr. Segal is the co founder of Repare Therapeutics, Inc., a clinical stage oncology drug developer, and served as its President and Chief Executive Officer and as a member of the board of directors, since its incorporation in 2016 through April 2025. From February 2010 to January 2016, he was a Managing Partner with Persistence Capital Partners, a leading healthcare private equity investor. From June 2016 to March 2020, Mr. Segal served as Entrepreneur in Residence with Versant Ventures, a biotechnology venture capital firm based in San Francisco. Previously, Mr. Segal served as chief executive officer of everal emerging biotechnology companies including Caprion Pharmaceuticals (now CellCarta), Advanced Bioconcept and Thallion Pharmaceuticals. Mr. Segal previously served as Chairman of LMC Diabetes & Endocrinology, North America's largest community endocrinology and diabetes clinical and research practice, and Chairman of MedReleaf, until its $2.5 billion sale to Aurora Cannabis in 2018. He also previously served on the boards of directors of several public and private U.S. and Canadian companies. Mr. Segal received a BA in Politics from Brandeis University and an MBA from Harvard Business School. - Lloyd M. Segal ，他一直任职公司的董事会（2007年12月以来）。2010年2月以来，他一直担任Persistence Capital Partners公司（专注于医疗保健的私人股本基金）的普通合伙人。从1998年到2008年，他担任 Caprion Pharmaceuticals公司（于2007年成为Thallion Pharmaceuticals公司）的总裁兼首席执行官，在那里他仍然是董事会主席。他此前曾担任McKinsey公司的管理顾问，以及Advanced Bioconcept公司的总裁兼首席执行官。他目前任职Thallion Pharmaceuticals公司和 GBC American Growth Fund公司的董事会，以及 the School of Science at Brandeis University的顾问委员会。
- Lloyd M. Segal has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Mr. Segal is the co founder of Repare Therapeutics, Inc., a clinical stage oncology drug developer, and served as its President and Chief Executive Officer and as a member of the board of directors, since its incorporation in 2016 through April 2025. From February 2010 to January 2016, he was a Managing Partner with Persistence Capital Partners, a leading healthcare private equity investor. From June 2016 to March 2020, Mr. Segal served as Entrepreneur in Residence with Versant Ventures, a biotechnology venture capital firm based in San Francisco. Previously, Mr. Segal served as chief executive officer of everal emerging biotechnology companies including Caprion Pharmaceuticals (now CellCarta), Advanced Bioconcept and Thallion Pharmaceuticals. Mr. Segal previously served as Chairman of LMC Diabetes & Endocrinology, North America's largest community endocrinology and diabetes clinical and research practice, and Chairman of MedReleaf, until its $2.5 billion sale to Aurora Cannabis in 2018. He also previously served on the boards of directors of several public and private U.S. and Canadian companies. Mr. Segal received a BA in Politics from Brandeis University and an MBA from Harvard Business School.
- Oleg Nodelman
-
Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
Oleg Nodelman has served as a member of Anaptysbio, Inc.'s Board since April 2021 and will be Chairman of Anaptysbio, Inc.'s Board effective immediately following the Annual Meeting. Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech focused investment advisory firm established in 2013, and one of Anaptysbio, Inc.'s principal stockholders, since its inception. Previously, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman currently serves on the board of directors of both Galapagos NV and Zymeworks, and previously served on the board of directors of Prothena Corporation plc from 2019 to 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021. - Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
- Oleg Nodelman has served as a member of Anaptysbio, Inc.'s Board since April 2021 and will be Chairman of Anaptysbio, Inc.'s Board effective immediately following the Annual Meeting. Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech focused investment advisory firm established in 2013, and one of Anaptysbio, Inc.'s principal stockholders, since its inception. Previously, Mr. Nodelman served as a Portfolio Manager at BVF Partners from 2001 to 2012. Mr. Nodelman earned a B.S.F.S. in Science and Technology from Georgetown University, School of Foreign Service in 1999. Mr. Nodelman currently serves on the board of directors of both Galapagos NV and Zymeworks, and previously served on the board of directors of Prothena Corporation plc from 2019 to 2024, Nuvation Bio Inc. from February 2021 to December 2023 and Panacea Acquisition Corp. II from April 2020 to February 2021.
高管简历
中英对照 | 中文 | 英文- Kyle D. Kuvalanka
Kyle D. Kuvalanka自2015年9月起担任首席运营官。在加入Syros之前，Kuvalanka先生于2013年9月至2015年9月期间担任生物制药公司Blueprint Medicines Corporation的首席业务官兼首席财务和会计官。Kuvalanka先生于2002年至2013年9月期间任职于Takeda Pharmaceutical Company以及在被Takeda收购之前任职于Millennium Pharmaceuticals，Inc.，包括于2009年至2013年9月期间担任副总裁，负责公司战略、业务发展和联盟管理。Kuvalanka先生拥有Wesleyan大学的学士学位和Pennsylvania大学Wharton商学院的工商管理硕士学位。
Kyle D. Kuvalanka has served as Aktis Oncology, Inc.'s Chief Financial Officer since November 2025. Mr. Kuvalanka previously served as Chief Financial Officer and Chief Business Officer of ROME Therapeutics, Inc. since November 2023. Prior to ROME Therapeutics, from April 2020 to April 2023, he served as the Chief Financial Officer and Chief Operating Officer of Goldfinch Bio, Inc., or Goldfinch. In January 2023, Goldfinch initiated an Assignment for the Benefit of Creditors pursuant to Delaware state law. From April 2021 until September 2023, Mr. Kuvalanka served as a member of the board of directors and audit chair of IMV Inc., or IMV, a clinical stage biopharmaceuticals company. In December 2023, IMV filed an assignment pursuant to section 49(1) of the Bankruptcy and Insolvency Act (Canada) voluntarily declaring bankruptcy. Previously, Mr. Kuvalanka served as the Chief Operating Officer and Principal Financial and Accounting Officer of Syros Pharmaceuticals (Nasdaq: SYRS) and Chief Business Officer and Principal Financial and Accounting Officer of Blueprint Medicines Corporation (Nasdaq: BPMC). From 2002 to September 2013, Mr. Kuvalanka worked at Takeda Pharmaceuticals and at Millennium prior to its takeover by Takeda, including as vice president, corporate strategy, business development and alliance management from 2009 to September 2013. Mr. Kuvalanka holds a BA from Wesleyan University and an MBA from The Wharton Business School of the University of Pennsylvania.- Kyle D. Kuvalanka自2015年9月起担任首席运营官。在加入Syros之前，Kuvalanka先生于2013年9月至2015年9月期间担任生物制药公司Blueprint Medicines Corporation的首席业务官兼首席财务和会计官。Kuvalanka先生于2002年至2013年9月期间任职于Takeda Pharmaceutical Company以及在被Takeda收购之前任职于Millennium Pharmaceuticals，Inc.，包括于2009年至2013年9月期间担任副总裁，负责公司战略、业务发展和联盟管理。Kuvalanka先生拥有Wesleyan大学的学士学位和Pennsylvania大学Wharton商学院的工商管理硕士学位。
- Kyle D. Kuvalanka has served as Aktis Oncology, Inc.'s Chief Financial Officer since November 2025. Mr. Kuvalanka previously served as Chief Financial Officer and Chief Business Officer of ROME Therapeutics, Inc. since November 2023. Prior to ROME Therapeutics, from April 2020 to April 2023, he served as the Chief Financial Officer and Chief Operating Officer of Goldfinch Bio, Inc., or Goldfinch. In January 2023, Goldfinch initiated an Assignment for the Benefit of Creditors pursuant to Delaware state law. From April 2021 until September 2023, Mr. Kuvalanka served as a member of the board of directors and audit chair of IMV Inc., or IMV, a clinical stage biopharmaceuticals company. In December 2023, IMV filed an assignment pursuant to section 49(1) of the Bankruptcy and Insolvency Act (Canada) voluntarily declaring bankruptcy. Previously, Mr. Kuvalanka served as the Chief Operating Officer and Principal Financial and Accounting Officer of Syros Pharmaceuticals (Nasdaq: SYRS) and Chief Business Officer and Principal Financial and Accounting Officer of Blueprint Medicines Corporation (Nasdaq: BPMC). From 2002 to September 2013, Mr. Kuvalanka worked at Takeda Pharmaceuticals and at Millennium prior to its takeover by Takeda, including as vice president, corporate strategy, business development and alliance management from 2009 to September 2013. Mr. Kuvalanka holds a BA from Wesleyan University and an MBA from The Wharton Business School of the University of Pennsylvania.
- Matthew Roden
Matthew Roden担任我们的董事会主席。Roden博士在整个医疗保健生态系统积累了广泛的经验，曾担任大型生物制药公司的高级领导者，领导了股权资本市场的生物技术研究，并磨练了他作为免疫学家和结构生物学家的科学基础。Roden博士目前担任Aktis Oncology的总裁兼首席执行官，以及MPM Capital的执行合伙人。他也是iTeos Therapeutics NASDAQ:ITOS、Aktis Oncology和NextPoint Therapeutics的董事会成员。从2019年到2020年，Roden博士担任百时美施贵宝BMS的高级副总裁兼企业战略主管。在此职位上，Roden博士为合并的BMS-Celgene实体和初始投资组合优化提供了首个战略计划。从2016年到2019年，他担任战略公司发展和全球BD评估主管，负责并购，结构化交易，战略股权投资和资产剥离，以及所有治疗类别的领先业务发展搜索和评估（S&E）活动。Roden博士还曾在代表外部创新的研发领导团队中任职。Roden博士领导或监督了100多项业务开发交易，这些交易的累计价值超过1250亿美元，包括BMS’；收购Celgene，这是迄今为止医疗保健领域最大的收购。他曾担任瑞银投资银行的生物技术股票研究主管；摩根大通和美国银行美林的高级生物技术股票分析师；以及瑞士信贷第一波士顿的合伙人。除了对整个生物技术领域的研究报道外，罗登博士和他的团队还在2005年至2016年期间提供了24次股票发行的股票研究尽职调查和投资者参与，初始价值总计33亿美元。他在爱因斯坦医学院获得博士学位，主要研究免疫相关分子的结构生物学。在完成这项研究生工作之前，他在马里兰州贝塞斯达的国家癌症研究所获得了免疫肿瘤学的博士后临床研究奖学金。Roden博士拥有乔治敦大学的硕士学位和乔治梅森大学的学士学位。
Matthew Roden has served as Aktis Oncology, Inc.'s President and Chief Executive Officer and as a member of Aktis Oncology, Inc.'s board of directors since September 2020. Since August 2020, Dr. Roden has worked as an Entrepreneur Partner at MPM BioImpact LLC, a biotechnology investment firm. Dr. Roden also serves as a member of the board of directors of Orna Therapeutics, Inc., a biotechnology company, since May 2024 following its acquisition of ReNAgade Therapeutics Inc. where he had served on the board of directors since January 2023. Previously, Dr. Roden served on the board of directors of NextPoint Therapeutics, Inc., a clinical stage biotechnology company, from October 2020 to December 2024, iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical stage biopharmaceutical company, from November 2020 to February 2023, and as Chairman of Tumeric Acquisition Corporation, a special purpose acquisition company, from September 2020 to December 2022. From November 2019 to August 2020, he was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb, a global pharmaceutical company. From May 2016 to November 2019, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global Business Development Assessment at Bristol Myers Squibb, leading business development search and evaluation activities for all therapeutic categories. Dr. Roden also previously worked as an equity research analyst at UBS Investment Bank and J.P. Morgan. Dr. Roden holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, an MS from Georgetown University, a BS from George Mason University and was a pre doctoral fellow at the National Cancer Institute.- Matthew Roden担任我们的董事会主席。Roden博士在整个医疗保健生态系统积累了广泛的经验，曾担任大型生物制药公司的高级领导者，领导了股权资本市场的生物技术研究，并磨练了他作为免疫学家和结构生物学家的科学基础。Roden博士目前担任Aktis Oncology的总裁兼首席执行官，以及MPM Capital的执行合伙人。他也是iTeos Therapeutics NASDAQ:ITOS、Aktis Oncology和NextPoint Therapeutics的董事会成员。从2019年到2020年，Roden博士担任百时美施贵宝BMS的高级副总裁兼企业战略主管。在此职位上，Roden博士为合并的BMS-Celgene实体和初始投资组合优化提供了首个战略计划。从2016年到2019年，他担任战略公司发展和全球BD评估主管，负责并购，结构化交易，战略股权投资和资产剥离，以及所有治疗类别的领先业务发展搜索和评估（S&E）活动。Roden博士还曾在代表外部创新的研发领导团队中任职。Roden博士领导或监督了100多项业务开发交易，这些交易的累计价值超过1250亿美元，包括BMS’；收购Celgene，这是迄今为止医疗保健领域最大的收购。他曾担任瑞银投资银行的生物技术股票研究主管；摩根大通和美国银行美林的高级生物技术股票分析师；以及瑞士信贷第一波士顿的合伙人。除了对整个生物技术领域的研究报道外，罗登博士和他的团队还在2005年至2016年期间提供了24次股票发行的股票研究尽职调查和投资者参与，初始价值总计33亿美元。他在爱因斯坦医学院获得博士学位，主要研究免疫相关分子的结构生物学。在完成这项研究生工作之前，他在马里兰州贝塞斯达的国家癌症研究所获得了免疫肿瘤学的博士后临床研究奖学金。Roden博士拥有乔治敦大学的硕士学位和乔治梅森大学的学士学位。
- Matthew Roden has served as Aktis Oncology, Inc.'s President and Chief Executive Officer and as a member of Aktis Oncology, Inc.'s board of directors since September 2020. Since August 2020, Dr. Roden has worked as an Entrepreneur Partner at MPM BioImpact LLC, a biotechnology investment firm. Dr. Roden also serves as a member of the board of directors of Orna Therapeutics, Inc., a biotechnology company, since May 2024 following its acquisition of ReNAgade Therapeutics Inc. where he had served on the board of directors since January 2023. Previously, Dr. Roden served on the board of directors of NextPoint Therapeutics, Inc., a clinical stage biotechnology company, from October 2020 to December 2024, iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical stage biopharmaceutical company, from November 2020 to February 2023, and as Chairman of Tumeric Acquisition Corporation, a special purpose acquisition company, from September 2020 to December 2022. From November 2019 to August 2020, he was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb, a global pharmaceutical company. From May 2016 to November 2019, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, and concurrently served as Head of Global Business Development Assessment at Bristol Myers Squibb, leading business development search and evaluation activities for all therapeutic categories. Dr. Roden also previously worked as an equity research analyst at UBS Investment Bank and J.P. Morgan. Dr. Roden holds a PhD in Microbiology and Immunology from the Albert Einstein College of Medicine, an MS from Georgetown University, a BS from George Mason University and was a pre doctoral fellow at the National Cancer Institute.
- Paul L. Feldman
Paul L. Feldman自2020年12月起担任首席科学官。Previoly，Dr. Feldman是Phoundry Pharmaceuticals，Inc.的联合创始人和首席执行官，此前该公司于2015年被生物制药公司Intarcia Therapeutics，Inc.收购。费尔德曼博士随后在Intarcia担任执行管理团队的五年时间，担任发现和转化医学负责人，领导发现和开发治疗代谢疾病的新型多肽疗法，直到2020年12月。在担任Phoundry和Intarcia职务之前，他在跨国制药和生物技术公司葛兰素史克（NYSE：GSK）工作了超过27年，在那里他参与了五种获批药物的发现。费尔德曼博士还担任脊索瘤基金会的董事会成员。费尔德曼博士拥有加州大学伯克利分校化学博士学位和杜克大学化学学士学位。
Paul L. Feldman has served as Aktis Oncology, Inc.'s Chief Scientific Officer since December 2020. Previously, Dr. Feldman was the Co Founder and Chief Executive Officer of Phoundry Pharmaceuticals, Inc. before it was acquired by Intarcia Therapeutics, Inc., a biopharmaceutical company, in 2015. Dr. Feldman then spent five years at Intarcia on the executive management team as Head of Discovery and Translational Medicine leading the discovery and development of novel peptide therapeutics to treat metabolic disease until December 2020. Prior to his roles at Phoundry and Intarcia, he worked more than 27 years at GlaxoSmithKline (NYSE: GSK), a multinational pharmaceutical and biotechnology company, where he was part of the discovery of five approved drugs. Dr. Feldman also serves on the board of directors of the Chordoma Foundation. Dr. Feldman holds a PhD in Chemistry from the University of California, Berkeley and BS in Chemistry from Duke University.- Paul L. Feldman自2020年12月起担任首席科学官。Previoly，Dr. Feldman是Phoundry Pharmaceuticals，Inc.的联合创始人和首席执行官，此前该公司于2015年被生物制药公司Intarcia Therapeutics，Inc.收购。费尔德曼博士随后在Intarcia担任执行管理团队的五年时间，担任发现和转化医学负责人，领导发现和开发治疗代谢疾病的新型多肽疗法，直到2020年12月。在担任Phoundry和Intarcia职务之前，他在跨国制药和生物技术公司葛兰素史克（NYSE：GSK）工作了超过27年，在那里他参与了五种获批药物的发现。费尔德曼博士还担任脊索瘤基金会的董事会成员。费尔德曼博士拥有加州大学伯克利分校化学博士学位和杜克大学化学学士学位。
- Paul L. Feldman has served as Aktis Oncology, Inc.'s Chief Scientific Officer since December 2020. Previously, Dr. Feldman was the Co Founder and Chief Executive Officer of Phoundry Pharmaceuticals, Inc. before it was acquired by Intarcia Therapeutics, Inc., a biopharmaceutical company, in 2015. Dr. Feldman then spent five years at Intarcia on the executive management team as Head of Discovery and Translational Medicine leading the discovery and development of novel peptide therapeutics to treat metabolic disease until December 2020. Prior to his roles at Phoundry and Intarcia, he worked more than 27 years at GlaxoSmithKline (NYSE: GSK), a multinational pharmaceutical and biotechnology company, where he was part of the discovery of five approved drugs. Dr. Feldman also serves on the board of directors of the Chordoma Foundation. Dr. Feldman holds a PhD in Chemistry from the University of California, Berkeley and BS in Chemistry from Duke University.
- Shulamit Ron Bigger
Shulamit Ron Bigger自2022年9月起担任首席运营官。Previoly，Ron Bigger博士于2021年3月至2022年9月期间担任Bristol Myers Squibb研究和早期开发组织的投资组合战略副总裁，负责领导投资组合和项目战略、预算管理以及运营模型设计及其实施。2017年11月开始，Ron Bigger博士在百时美施贵宝任职期间，还在美国和全球市场担任过多个战略和商业角色。在担任百时美施贵宝之前，她曾担任大型制药公司的战略顾问，并曾在以色列国防军担任人力资源官。Ron Bigger博士拥有杰拉勒姆希伯来大学癌症表观遗传学博士学位和以色列理工学院分子生物化学学士学位。
Shulamit Ron Bigger has served as Aktis Oncology, Inc.'s Chief Operating Officer since September 2022. Previously, Dr. Ron Bigger served as the Vice President, Portfolio Strategy for the Research and Early Development organization at Bristol Myers Squibb, from March 2021 until September 2022, where she led portfolio and program strategy, budget management, and operating model design and its implementation. Dr. Ron Bigger also held various strategic and commercial roles in both United States and global markets while at Bristol Myers Squibb beginning in November of 2017. Prior to her roles at Bristol Myers Squibb, she worked as a strategic consultant to large pharmaceutical companies and served as a Human Resource officer in the Israeli Defense Forces. Dr. Ron Bigger holds a PhD in Cancer Epigenetics from The Hebrew University of Jerusalem and a BA in Molecular Biochemistry from Technion – Israel Institute of Technology.- Shulamit Ron Bigger自2022年9月起担任首席运营官。Previoly，Ron Bigger博士于2021年3月至2022年9月期间担任Bristol Myers Squibb研究和早期开发组织的投资组合战略副总裁，负责领导投资组合和项目战略、预算管理以及运营模型设计及其实施。2017年11月开始，Ron Bigger博士在百时美施贵宝任职期间，还在美国和全球市场担任过多个战略和商业角色。在担任百时美施贵宝之前，她曾担任大型制药公司的战略顾问，并曾在以色列国防军担任人力资源官。Ron Bigger博士拥有杰拉勒姆希伯来大学癌症表观遗传学博士学位和以色列理工学院分子生物化学学士学位。
- Shulamit Ron Bigger has served as Aktis Oncology, Inc.'s Chief Operating Officer since September 2022. Previously, Dr. Ron Bigger served as the Vice President, Portfolio Strategy for the Research and Early Development organization at Bristol Myers Squibb, from March 2021 until September 2022, where she led portfolio and program strategy, budget management, and operating model design and its implementation. Dr. Ron Bigger also held various strategic and commercial roles in both United States and global markets while at Bristol Myers Squibb beginning in November of 2017. Prior to her roles at Bristol Myers Squibb, she worked as a strategic consultant to large pharmaceutical companies and served as a Human Resource officer in the Israeli Defense Forces. Dr. Ron Bigger holds a PhD in Cancer Epigenetics from The Hebrew University of Jerusalem and a BA in Molecular Biochemistry from Technion – Israel Institute of Technology.
- Akos Czibere
Akos Czibere自2024年7月起担任首席医疗官。从2017年4月到2024年7月，Czibere博士在辉瑞担任越来越多的职责，最近担任副总裁治疗领域负责人，负责血液学—肿瘤学，负责多个项目的战略和执行。在此之前，Czibere博士在Merrimack制药拥有越来越多的资历。Czibere博士拥有德国杜塞尔多夫大学的医学博士和博士学位。Czibere博士在哈佛医学院进行了博士后研究金。
Akos Czibere has served as Aktis Oncology, Inc.'s Chief Medical Officer since July 2024. From April 2017 through July 2024, Dr. Czibere held increasing roles of responsibility at Pfizer, most recently serving as Vice President Therapeutic Area Head of Hematology —Oncology, where he was responsible for strategy and execution across multiple programs. Prior to that, Dr. Czibere held increasing levels of seniority at Merrimack Pharmaceuticals. Dr. Czibere holds an MD and PhD from the University of Duesseldorf, Germany. Dr. Czibere conducted a Postdoctoral Fellowship at Harvard Medical School.- Akos Czibere自2024年7月起担任首席医疗官。从2017年4月到2024年7月，Czibere博士在辉瑞担任越来越多的职责，最近担任副总裁治疗领域负责人，负责血液学—肿瘤学，负责多个项目的战略和执行。在此之前，Czibere博士在Merrimack制药拥有越来越多的资历。Czibere博士拥有德国杜塞尔多夫大学的医学博士和博士学位。Czibere博士在哈佛医学院进行了博士后研究金。
- Akos Czibere has served as Aktis Oncology, Inc.'s Chief Medical Officer since July 2024. From April 2017 through July 2024, Dr. Czibere held increasing roles of responsibility at Pfizer, most recently serving as Vice President Therapeutic Area Head of Hematology —Oncology, where he was responsible for strategy and execution across multiple programs. Prior to that, Dr. Czibere held increasing levels of seniority at Merrimack Pharmaceuticals. Dr. Czibere holds an MD and PhD from the University of Duesseldorf, Germany. Dr. Czibere conducted a Postdoctoral Fellowship at Harvard Medical School.
- Tyler Benedum
Tyler Benedum自2024年5月起担任首席技术官，在此之前，他自2022年1月起担任CMC高级副总裁。在加入Aktis之前，从2005年8月到2022年1月，Benedum博士在Avid RadioPharmaceuticals Inc.（被礼来公司收购）担任越来越资深的职位，最近担任其CMC开发和制造副总裁。Benedum博士在华盛顿学院获得化学学士学位，在弗吉尼亚大学获得有机化学博士学位。随后，他在匹兹堡大学完成了天然产物合成方面的博士后研究金。
Tyler Benedum has served as Aktis Oncology, Inc.'s Chief Technical Officer since May 2024, prior to which he served as Aktis Oncology, Inc.'s Senior Vice President, CMC since January 2022. Previous to joining Aktis, from August 2005 to January 2022, Dr. Benedum held positions of increasing seniority at Avid RadioPharmaceuticals Inc. (acquired by Eli Lilly and Company), most recently serving as its Vice President of CMC Development and Manufacturing. Dr. Benedum received a BS in Chemistry from Washington College and a PhD in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship in natural product synthesis at the University of Pittsburgh.- Tyler Benedum自2024年5月起担任首席技术官，在此之前，他自2022年1月起担任CMC高级副总裁。在加入Aktis之前，从2005年8月到2022年1月，Benedum博士在Avid RadioPharmaceuticals Inc.（被礼来公司收购）担任越来越资深的职位，最近担任其CMC开发和制造副总裁。Benedum博士在华盛顿学院获得化学学士学位，在弗吉尼亚大学获得有机化学博士学位。随后，他在匹兹堡大学完成了天然产物合成方面的博士后研究金。
- Tyler Benedum has served as Aktis Oncology, Inc.'s Chief Technical Officer since May 2024, prior to which he served as Aktis Oncology, Inc.'s Senior Vice President, CMC since January 2022. Previous to joining Aktis, from August 2005 to January 2022, Dr. Benedum held positions of increasing seniority at Avid RadioPharmaceuticals Inc. (acquired by Eli Lilly and Company), most recently serving as its Vice President of CMC Development and Manufacturing. Dr. Benedum received a BS in Chemistry from Washington College and a PhD in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship in natural product synthesis at the University of Pittsburgh.